

## **W18**

### **Is it possible to eradicate HCV infections through primary care screening?**

*Santiago Pérez Cachafeiro(1), E Poveda Lopez(2), N Otero Leiro(3), R Martínez Liñares(3), SM Ayude Díaz(4), PP Pilar Rodríguez Casal(5)*

*(1) Cambados Health Centre. EOXI Pontevedra e O Salnés*

*(2) INIBIC - Institute of Biomedical Research of A Coruña*

*(3) O Grove Health Centre. EOXI Pontevedra e O Salnés*

*(4) Lerez Health Centre. EOXI Pontevedra e O Salnés*

*(5) Marín Health Centre. EOXI Pontevedra e O Salnés*

*Corresponding author: Dr Santiago Pérez Cachafeiro, Servizo Galego De Saúde, EOXI Pontevedra-Salnés, Cambados, Pontevedra, Spain. E-mail: [santiago.perez.cachafeiro@sergas.es](mailto:santiago.perez.cachafeiro@sergas.es)*

**Background & Aim:** HCV is considered a Public Health Problem. 130-180 millions are infected (3% of the global population). It causes 350.000-500.000 annual deaths and there is no vaccine. The ECDC recommendations are based on the promotion of strategies aimed at key populations at risk to enable early diagnosis of infection.

**Method:** Firstly, our experts will explain the following topics (30 minutes)

1. New treatments for HCV

2. Impact of a screening HCV programme at A Coruña Primary Care Health Area

3. Economic aspects of HCV treatment

4. Proposing the design of a new HCV screening educational tool for Primary Care in Europe. Afterwards, we will split the audience on several groups (6pax) to discuss how will they address HCV screening on their Primary Care Areas. They should address barriers and facilitators to HCV screening may appear on their context. Different approaches suggested by groups will be debated through an open discussion. Solutions to avoid barriers and enhance facilitators will be proposed by our team. The final aim of this workshop is to facilitate tools to promote HCV screening around European Primary Care Clinics, and to find partners interested on HCV. We want to develop an HCV Educational Tool for Primary Care Screening. Funding: Santiago Pérez has received financial aid from Abbvie and PWC regarding prior scientific works and travel expenses related to Hepatitis C Screening at Primary Care Level.